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summary
Impaired diffusing capacity of the lung for carbon monoxide (DLCO) was frequently observed in systemic 
sclerosis (SSc) patients, generally related to the presence of interstitial lung disease (ILD) and/or pulmonary 
arterial hypertension (PAH). However, in clinical practice abnormally low DLCO values may be found also in 
the absence of these SSc complications. The objective was to investigate the prospective clinical relevance of 
isolated DLCO reduction at baseline in SSc patients.
Ninety-seven SSc female patients (age at the diagnosis: 51.3±14.5 years; disease duration: 10.4±6.6 years; 
limited/diffuse skin subsets: 92/5), without any clinical, radiological (high resolution computed tomography), 
and echocardiographic manifestations of ILD or PAH at baseline, nor other lung or heart diseases able to affect 
DLCO, were recruited at our Rheumatology Centre. 
Patients with DLCO <55% (15 patients; group A) were compared with those with normal DLCO (82 patients; 
group B), at baseline and at the end of follow-up. 
At baseline, patients of group A showed significantly higher percentage of anticentromere autoantibodies com-
pared to group B (13/15, 86.6% vs 48/82, 58.5%; p=0.044). More interestingly, at the end of long-lasting 
clinical follow-up (11.6±6.7 years), pre-capillary PAH (right heart catheterization) solely developed in some 
patients of group A (3/15, 20% vs 0/82; p=0.003).
In SSc patients, the presence at baseline of isolated, marked DLCO reduction (<55% of predicted) and serum 
anticentromere autoantibodies might characterize a peculiar SSc subset that may precede the development of 
PAH. Therefore, careful clinical follow-up of patients with isolated moderate-severe DLCO reduction should 
be mandatory.
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n	 IntroductIon
Systemic sclerosis (SSc) is a connec-tive tissue disease characterized by 
excessive production of fibrotic tissue and 
endothelial dysfunction (1). The latter is 
responsible of widespread microvascular 
damage, leading to Raynaud’s phenom-
enon, ischemic digital ulcers, pulmonary 
arterial hypertension (PAH), and/or renal 
crisis. Indeed, the clinical features of SSc 
patients may be widely variable, from 
subclinical vascular abnormalities, until 
severe life-threatening organ involvement 
(2). Therefore, long-term follow-up of 
SSc patients is recommendable, in order 
to diagnose SSc vascular complications 
precociously, with timely therapeutic ap-
proach. Namely, PAH is one of the most se-
rious complications of SSc, characterized 
by very poor 5-year prognosis, generally 
worse than that observed in patients with 
idiopathic PAH (3). Besides, the availabil-
ity of novel treatments for PAH, mainly the 
anti-endothelin antagonists, has given the 
hope to counteract this devastating compli-
cation; therefore, early diagnosis of SSc-
associated PAH may be decisive for the 
overall disease outcome (4). Transthoracic 
color-Doppler echocardiography is a non-
invasive, reproducible, widely available 
tool to accurately estimate pulmonary arte-
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rial pressure and to evaluate right ventricle 
performance (5). PAH is suspected if the 
peak velocity of tricuspid regurgitation is 
>3 meters/second, with consequent sys-
tolic pulmonary arterial pressure (PAPs) 
resulted >35 mmHg (6); in this case, the 
right heart catheterization is mandatory 
in order to confirm the vascular alteration 
and to distinguish between pre-capillary 
and post-capillary PAH (5, 6). Apart from 
cardiac ultrasonography, the presence of 
PAH can be suspected on the basis of the 
reduction of diffusing capacity of the lung 
for carbon monoxide (DLCO), mainly in 
absence of interstitial lung disease (ILD) 
(7). Recently, an international cross-sec-
tional study (DETECT study) proposed an 
algorithm, in order to identify PAH in SSc 
patients and to minimise missed diagnoses 
(8). This tool includes forced vital capac-
ity (FVC)%/DLCO% ratio, telangiectasias, 
anticentromere antibodies, NTproBNP, se-
rum urate, and right axis deviation at elec-
trocardiogram, as parameters to be consid-
ered in order to select patients who should 
perform echocardiography. In the second 
step, the referral to right heart catheteriza-
tion was decided after considering right 
atrium area and tricuspid regurgitant jet ve-
locity (TV) at echocardiography. 
Interestingly, a few SSc patients may pres-
ent an apparently isolated reduction of 
DLCO, without evidencing ILD at chest 
high-resolution computed tomography 
(HRCT) and with normal parameters (i.e., 
TV) at echocardiographic evaluation. Giv-
en the proper execution of the test, with 
correction for patients’ hemoglobin levels 
(9), and by excluding other known causes 
that may reduce DLCO, the clinico-prog-
nostic significance of this finding remains 
unknown. Hypothetically, SSc-related sub-
clinical microvascular lung involvement 
could be suspected, which may potentially 
evolve into overt PAH. A predictive role of 
DLCO reduction, at different cut-off levels, 
for PAH development has been suggested 
with variable sensitivity and specificity 
(10); however, these previous studies ana-
lyzed the predictive value of DLCO reduc-
tion in the setting of patients with one or 
more cardio-pulmonary parameter altera-
tions. On the other hand, the long-term out-
come of SSc patients with isolated DLCO 
impairment was investigated by Steen et al. 
(11) in a cohort of 152 subjects recruited 
from 1972 to 1987. Among these patients 
with a mean initial DLCO value of 48% of 
predicted, 11% developed PAH (p<0.01); 
moreover, the best predictor for isolat-
ed pulmonary hypertension was a FVC/
DLCO ratio >1.4.
The aim of the present study is to inves-
tigate the clinico-prognostic relevance of 
isolated DLCO reduction during the fol-
low-up of a cohort of SSc patients in ab-
sence of other cardio-pulmonary manifes-
tations evaluated by means of chest HRCT 
and echocardiography.  
n	 MATERIALS AND METHODS
Ninety-seven SSc patients [mean age at 
the diagnosis 51.3±14.5 standard deviation 
(SD) years, disease duration at the end of 
follow-up 10.4±6.6 SD years] referring at 
our University-based Rheumatology Cen-
tre from January 1st 2002 until December 
31th 2012 were considered. All patients 
were diagnosed by trained rheumatologists 
with consolidated expertise in SSc; more-
over, they fulfilled the 2013 American Col-
lege of Rheumatology (ACR)/European 
League Against Rheumatism (EULAR) 
Classification Criteria for SSc (12). At 
baseline, the inclusion criteria to enter into 
the study were:
1) absence of dyspnea [New York Heart 
Association (NYHA) III-IV];
2) absence of ILD at chest HRCT;
3) FVC >80%;
4) normal echocardiography, namely with-
out increase of the right atrial or ventric-
ular areas and peak velocity of tricuspid 
regurgitation <3 meters/second;
5) absence of chronic obstructive pulmo-
nary disease, heart failure or valvular 
heart diseases.
The patients were divided in two groups 
according to the DLCO values, consider-
ing as cut-off DLCO < 55%, as proposed 
by Steen et al. (11).
Pulmonary function tests were performed 
using the spirometer MasterScreen Body 
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(Jaeger-Toennies, Hoechberg, Germany); 
DLCO was measured by a single-breath 
technique and corrected for hemoglobin. 
Results were expressed as the percentage of 
predicted values; values <80% of predicted 
were considered abnormal, using reference 
values of the Official Statement of the Eu-
ropean Respiratory Society. Chest HRCT 
scans were obtained using the LightSpeed 
VCT (GE Healthcare, Buckinghamshire, 
UK). One-mm sections were acquired 
at 10-mm intervals from apex to base of 
lungs, with the patients at full inspiration in 
a supine position. Additional scans in prone 
position were eventually recorded to evalu-
ate the effect of gravity-dependent opacifi-
cation. Echocardiographic measurements 
were performed with the subjects in partial 
left decubitus, by digital Vivid 7 ultrasound 
machine (GE-Vingmed, Horten, Norway). 
A variable frequency phased-array trans-
ducer (2.5-3.5-4.0 MHz) was used for 
two-dimensional, M-mode, and Doppler 
imaging. Left ventricular measures were 
obtained by M-mode with 2-D guidance at 
conventional levels, according to the Amer-
ican Society of Echocardiography recom-
mendations. Right ventricle (RV) end-
diastolic diameter was measured in apical 
four-chamber view at middle level. PAPs 
were estimated using Doppler recordings 
of tricuspid regurgitation, measuring the 
peak velocity of the tricuspid regurgita-
tion jet. According to the data of the French 
Nationwide Prospective Multicenter Study, 
we considered significant the peak velocity 
that resulted >3 meters/second (6). 
During the follow-up, spirometry with 
DLCO test and echocardiography were 
routinely performed yearly.
Table I - Clinical features of the whole systemic sclerosis series and 2 groups according to different DlCo values at baseline and at 
the end of follow-up.
Baseline End of Follow-up
ssc series Group a Group B
p
ssc series Group a Group B
pNo. 97 (DLCO <55%) (DLCO ≥55%) No. 97 (DLCO <55%) (DLCO ≥55%)
N=15 N=82 N=15 N=82
age (years) 51.3±14.5 52.9±10.5 49±13.6 ns 60.1±12.6 64.4±9.8 59.3±13 ns
Dis. duration (years) 1 (0-28)* 2 (0-13)1 1 (0-28)* ns 10.4±6.6 11.5±7.1 10.3±6.3 ns
Skin subset (l/D) 93/4 14/1 79/3 ns 92/5 14/1 78/4 ns
Digital ulcers° 22 (22.7%) 3 (20%) 19 (23.2%) ns 32 (33%) 6 (40%) 26 (31.7%) ns
esophageal involvement 51 (52.6%) 9 (60%) 42 (51.2%) ns 60 (61.8%) 11 (73.3%) 49 (59.7%) ns
aCa 61 (62.9%) 13 (86.6%) 48 (58.5%) 0.044
anti-Scl70 28 (28.9%) 2 (13.3%) 26 (31.7%) ns
anoa 6 (6.2%) 0 6 (7.3%) ns
Heart involvement 0 0 0 ns 4 (4.1%) 2 (13.3%) 2 (2.4%) ns
lung fibrosis 0 0 0 ns 14 (14.4%) 4 (26.7%) 9 (11%) ns
FVC% 106.7±13.8 106.3±13 106.6±14.1 ns 107.7±17.6 101.8±18 108.1±18.6 ns
DlCo% 65.3±16.5 46±6.9 75.2±14.4 <0.001 64.6±15.7 44.5±7 68.2±14 <0.001
FVC/DlCo>1.6 97 (30.9%) 15 (100%) 15 (18.3%) <0.001 58 (59.8%) 15 (100%) 43 (52.4%) <0.001
paH 0 0 0 ns 3 (3.1%) 3 (20%) 0 0.003
Treatment
 - iloprost# 10 (10.3%) 1 (6.7%) 9 (11%) ns
 - Bosentan§ 6 0 5 (6.1%) ns
SSc, systemic sclerosis; DlCo, diffusing capacity of the lung for carbon monoxide; Dis., disease; FVC, forced vital capacity; paH, 
pulmonary arterial hypertension. *Median (range); °at least one episode during the time period preceding the patients’ evaluation; #for 
at least 5 years before the last patients’ evaluation; §for at least 3 years before the last patients’ evalutation.
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Statistical analysis was performed in or-
der to investigate the possible correlations 
between SSc parameters and DLCO re-
duction. Values are given as mean±SD for 
normally distributed variables, or as me-
dian (range) for not normally distributed 
variables. Group values and proportions 
were compared by univariate analysis of 
variance (ANOVA) and Fisher’s exact test, 
respectively. 
n	 RESULTS
Demographic and clinico-serological fea-
tures of 97 SSc patients included in the 
study are shown in Table 1. Considering 
the 55% cut-off for DLCO, 15 patients 
with these DLCO levels were included 
in group A, while 82 constituted group B 
(DLCO ≥55%). 
All patients were females; except from 5 
cases, all individuals presented limited skin 
subset according to LeRoy’s classification 
(13). Moreover, 61 had anticentromere, 28 
anti-Scl70, and 7 anti-nucleolar autoanti-
bodies. According to inclusion criteria, no 
subject showed cardio-pulmonary manifes-
tations at baseline; consistently, mean FVC 
was 106.7±13.8%. Evaluating possible 
differences between the 2 subsets, a sig-
nificant higher frequency of ACA autoan-
tibodies was found in the first group [13/15 
(86.6%) vs 48/82 (58.5%); p=0.044]. 
At the end of the clinical follow-up 
(11.6±6.7 years), 14/97 patients developed 
ILD (4 in group A and 9 in group B; p=not 
significant), represented by mild bi-basilar 
fibrosis with ground-glass pattern at chest 
HRCT; indeed, mean FVC% values did not 
decrease significantly.
Of note, three subjects in group A devel-
oped pre-capillary PAH (p=0.003), diag-
nosed by right heart catheterization. At the 
end of follow-up, another patient in group 
A presented a new increase of PAPs mea-
sured by means of cardiac ultrasonogra-
phy, but suspected PAH was not confirmed 
at right heart catheterization. Interestingly, 
the disease duration of the patients with 
pre-capillary PAH was >20 years in 2, and 
8 years in the third one.
With regards to DLCO values, a significant 
deterioration (DLCO reduction >10% of 
baseline values) was observed in 19 patients 
of group B during the follow-up; among 
them, 9 cases presented DLCO values <55% 
at the end of the study. These subjects pre-
sented a disease duration of 14.1±8.1 years; 
7/9 were ACA positive and 4 out of them 
presented digital ulcers; one patient devel-
oped a diffuse skin involvement and lung fi-
brosis; in the end, the last patient developed 
a scleroderma renal crisis.
Concordantly to DLCO subsetting, a FVC/
DLCO ratio >1.6 was invariably (100%) 
observed in patients of group A and in 
18.3% of group B, respectively (p<0.001); 
this statistically significant difference 
among two groups was also present at the 
end of follow-up (100% vs 52.4%, respec-
tively; p<0.001).
The possible influence of vasoactive treat-
ments was also analyzed, particularly some 
therapies (i.e., iloprost, bosentan) frequently 
used in SSc patients with PAH. Indeed, even 
because of the low number of patients treat-
ed, no statistical correlations were recorded. 
n	 DISCUSSION
In the present study, the prospective clini-
cal significance of markedly low DLCO 
values, in absence of ILD or PAH at base-
line, was investigated. In particular, SSc 
patients with isolated reduction of DLCO 
(<55%) at the beginning of the follow-up 
showed higher prevalence of serum ACA 
autoantibodies compared to patients with 
normal DLCO values, as well as signifi-
cantly increased incidence of PAH. 
DLCO values represent a measure of the 
resistance encountered by gases during 
alveolar-capillary membrane diffusion. 
Therefore, every condition affecting the 
physiological gas exchanges may be esti-
mated by means of DLCO test (14). Im-
paired DLCO was frequently reported in 
SSc patients; two main pathological con-
ditions may be responsible of this altera-
tion, namely ILD and PAH (7, 15). The 
first one may affect DLCO levels by re-
ducing alveolar volume and/or by alveo-
lar–capillary membrane thickening (16). 
This latter may be impaired also by PAH, 
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in which vascular remodelling leads to 
arterial stiffness and vessel wall tighten-
ing (17). In our study, we selected SSc 
patients without any evidence of ILD or 
PAH at baseline, in order to eliminate 
the main causes of DLCO impairment. 
However, a significant group of patients 
(36/97; 37.1%) presented DLCO values 
<70%, not explained by other confound-
ing factors, such as anaemia, smoke habit, 
or presence of other lung or heart diseases 
known to influence the test (14). Isolated 
DLCO reduction has been reported in 
SSc, especially in patients with limited 
skin subset (18), consistently with our 
findings. 
In fact, DLCO impairment has been in-
cluded among diagnostic parameters 
in patients with early SSc (8, 19), also 
in absence of overt organ involvement. 
However, it is more difficult to attribute 
specific clinico-prognostic significance 
to this alteration, including possible early 
therapeutic attempts, in subjects generally 
asymptomatic or with very mild clinical 
symptoms. 
On the other hand, the presence of mod-
erate-severe reduction of DLCO, accord-
ingly to the cut-off level here employed 
(<55%), should induce at least patient’s 
careful evaluation and monitoring. It was 
well established that DLCO reduction is 
one of the best predictor of PAH devel-
opment, particularly in presence of FVC 
within normal range; namely, a FVC/
DLCO ratio of 1.6-1.8 helps to identify 
an increased likelihood of having PAH 
(11, 20). This issue has been focused by a 
multicenter cohort study for PAH assess-
ment and recognition of outcomes (21); 
in particular, SSc patients with DLCO 
<55% of predicted or FVC/DLCO >1.6, 
and PAPs >40 mmHg, were considered 
at-risk for PAH (22). However, consid-
ering patients with complicating PAH 
versus those without, low DLCO alone 
at baseline was not able to distinguish 
between two groups, even if it remains 
an important predictor of this complica-
tion. Moreover, severely reduced DLCO 
(<39%) at the time of PAH diagnosis 
seems to be a worse prognostic factor in 
SSc patients. Consistently, Arunthari et 
al. (23) did not found significant correla-
tions between right heart catheterization 
parameters and DLCO values in a cohort 
of 138 individuals, even when corrected 
for spirometric volumes. 
Accordingly, we did not found a signifi-
cant correlation between DLCO levels at 
baseline and PAH development consider-
ing a DLCO reduction <70% as cut-off 
(data not shown); otherwise, focusing on 
the patients’ subset with lower DLCO lev-
els (<55%) a statistically significant cor-
relation was observed. 
In the DETECT study (8), evaluating 466 
SSc patients at increased risk of PAH, a 
value of DLCO <60% was an inclusion cri-
terion; the 19% of these patients presented 
PAH, consistently with the findings of our 
present series (3/15, 20%). Nonetheless, 
other parameters have been encompassed 
in the DETECT algorithm, since also echo-
cardiography alone showed to be not so 
accurate for PAH identification (8). In this 
respect, considering our study, it cannot be 
excluded the possibility to have overlooked 
initial/mild PAH patients on the basis of 
normal findings obtained at the baseline 
echocardiography; however, this occur-
rence has been eventually offset by the 
long-lasting follow-up, including yearly 
echocardiographic evaluations.
With regards to other clinical SSc features, 
a trend to higher frequency of digital ulcers 
in patients with reduced DLCO was found 
at the end of follow-up. This findings, 
along with the significant presence of ACA 
autoantibodies and the pretension to PAH 
development, might define a peculiar SSc 
subset with significant vascular involve-
ment. As regards skin subset, the low num-
ber of patients with diffuse skin involve-
ment did not permit a conclusive statistical 
analysis.
In our patients’ series, disease duration 
seems to be quite relevant in the develop-
ment of PAH in two patients. In fact, 2/3 
subjects presented this complication after 
>20 years of follow-up; in particular, PAH 
appeared after 21 and 22 years from SSc 
diagnosis, respectively. This finding was 
not constantly reported in the few studies 
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previously published; Hsu et al. (22) in 
the PHAROS study observed the devel-
opment of PAH after 10.1±8.4 years from 
SSc onset. On the contrary, in a multicenter 
French study (24), PAH developed at any 
time after SSc diagnosis; in addition, pa-
tients with early-onset PAH were older 
at the time of SSc diagnosis compared to 
those without (25).
The possible usefulness of anti-endothelin 
receptor antagonists in preventing PAH re-
mains still to be verified.
A limit of our study is the relatively low 
number of patients taken into account with 
respect to the low incidence of PAH, one of 
the main SSc complication potentially cor-
related to reduced DLCO (26). However, 
this single Centre study firstly focused on 
particularly homogeneous subset of 15 SSc 
patients, with isolated marked reduction of 
DLCO in the absence of ILD or PAH, thor-
oughly evaluated by means of wide clinical 
and instrumental assessment; in addition, 
the patients were compared to a large con-
trol group, at baseline and after a long-term 
clinical follow-up for the detection of late 
SSc complications. 
Another limit of the study is that not all 
subjects underwent a right-heart-cathe-
terization during the follow-up period, 
because of the lack of suspect of PAH at 
echocardiography; indeed, SSc patients 
who developed PAH could be at least un-
derestimated, thus our findings might be 
further reinforced.
n	 CONCLUSIONS
In conclusion, it could be hypothesized 
that the presence of clear-cut isolated 
DLCO impairment, serum ACA autoan-
tibodies, and the propensity to develop 
PAH or digital ulcers might characterize 
a peculiar SSc subset; therefore, careful 
clinical follow-up of patients with iso-
lated DLCO reduction (<55%) should be 
mandatory in order to early detect the ap-
pearance of PAH, one of the most harm-
ful SSc complication. 
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